Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study-Reference-Cited by-同舟云学术

Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study

Published:2023-05 Issue:5 Volume:8 Page:968-979
ISSN:2468-0249
Container-title:Kidney International Reports
language:en
Short-container-title:Kidney International Reports

Author:

Rizk Dana V.,Rovin Brad H.^ORCID,Zhang Hong,Kashihara Naoki,Maes Bart,Trimarchi Hernán^ORCID,Perkovic Vlado,Meier Matthias,Kollins Dmitrij,Papachristofi Olympia,Charney Alan,Barratt Jonathan

Funder

Novartis

Novartis Pharma AG

Publisher

Elsevier BV

Subject

Nephrology

Reference41 articles.

1. IgA nephropathy;Wyatt;N Engl J Med,2013

2. IgA nephropathy;Lai;Nat Rev Dis Primers,2016

3. Natural history of primary IgA nephropathy;Berthoux;Semin Nephrol,2008

4. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population;Le;Nephrol Dial Transplant,2012

5. IgA nephropathy;Rodrigues;Clin J Am Soc Nephrol,2017

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Refractory IgA Nephropathy: A Challenge for Future Nephrologists;Medicina;2024-02-05

2. Novel Treatment Paradigms: Primary IgA Nephropathy;Kidney International Reports;2024-02

3. Synthesis and clinical application of new drugs approved by FDA in 2023;European Journal of Medicinal Chemistry;2024-02

4. Immunglobulin-A-Nephropathie – neue therapeutische Möglichkeiten;Die Innere Medizin;2024-01-31

5. Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy;Kidney International;2024-01